Featured Article

The researchers found 62.7% of patients in the study had a genetic change that increased their risk of adverse drug reactions when treated with one of five drugs.

Precision Oncology Today

Magazine

Uncovering the Mysteries of the Gut–Brain Connection

Links between the gut and the brain were discovered many years ago, but what role does the gut microbiome play in this relationship? Recent...
DNA molecule model. Glowing particles

5 Key Startups Bringing Digital Pathology Into Focus

Digital pathology is driving precision medicine by turbocharging the analysis of tissue slides. Here are the five top startups turning microscopy into a data...
drug modifying concept

How Is Artificial Intelligence Changing the Clinical Trials Landscape?

There is no doubt that artificial intelligence (AI) is currently en vogue. Many AI and machine-learning applications are already being deployed in drug discovery and development. Not only can AI process, analyze, and interpret huge datasets, it can also be used for structural drug design and toxicity and efficacy predictions.

Trending on Inside Precision Medicine

Brain tumour, illustration

Lurie Children’s Developing Optical Genome Mapping Test for Brain Tumors

Preliminary data suggests that about 30% of brain tumors show structural genomic variations.
spine bones injury

Study Shines Light on Hereditary Back Issues

European research involving three major biobanks has identified dozens of previously unidentified regions of the genome linked with disc herniation in the lumbar spine.
DNA with biological concept, 3d rendering.

Extrachromosomal DNA Spread Oncogenic Traits, Add Synthetic Lethal Targets

A trio of Nature articles reveal how extrachromosomal DNA (ecDNA) promotes cancer and how these circular molecules can be targeted therapeutically

Daily News

Related Content

Inside Precision Medicine